Easton Pharmaceuticals Buy Hold or Sell Recommendation

EAPH -- USA Stock  

USD 0.0026  0.00  0.00%

Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding Easton Pharmaceuticals is 'Strong Sell'. Macroaxis provides Easton Pharmaceuticals buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding EAPH positions. The advice algorithm takes into account all of Easton Pharmaceuticals available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from EAPH buy-and-hold prospective. Additionally see Easton Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for muliple equity instruments please use Instant Ratings tool.

Time Horizon

Risk Tolerance

Symbol
Execute Advice
Sell Easton PharmaceuticalsBuy Easton Pharmaceuticals
Strong Sell

Volatility

Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Not Available
For the selected time horizon Easton Pharmaceuticals has a mean deviation of 5.74, semi deviation of 0.0, standard deviation of 8.63, variance of 74.47, downside variance of 0.0 and semi variance of 0.0
We provide buy or sell advice to complement the prevailing expert consensus on Easton Pharmaceuticals. Our dynamic recommendation engine makes use of multi - dimensional algorithm to analyze the company potential to grow using all technical and fundamental data available at the time. To make sure Easton Pharmaceuticals is not overpriced, please confirm all Easton Pharmaceuticals fundamentals including its Debt to Equity and the relationship between Number of Employees and Z Score . As Easton Pharmaceuticals appears to be a penny stock we also advise to verify its Revenue numbers.

Easton Pharmaceuticals Trading Alerts and Improvement Suggestions

Easton Pharmaceuticals has very high historical volatility over the last 30 days
Easton Pharmaceuticals has some characteristics of a very speculative penny stock
Easton Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
The company reported previous year revenue of 67.43 K. Net Loss for the year was (526.78 K) with profit before overhead, payroll, taxes, and interest of 153 K.
EASTON PHARMACEUT currently holds about 5.81 K in cash with (155.6 K) of positive cash flow from operations.
Latest headline from www.prnewswire.com: Promedior Enters Into Definitive Merger Agreement To Be Acquired By Roche - PRNewswire

Easton Pharmaceuticals Returns Distribution Density

Mean Return0.2Value At Risk14.45
Potential Upside15.38Standard Deviation8.63
 Return Density 
      Distribution 

Easton Pharmaceuticals Greeks

α
Alpha over DOW
=0.32
β
Beta against DOW=1.74
σ
Overall volatility
=8.61
Ir
Information ratio =0.03

Easton Pharmaceuticals Volatility Alert

Easton Pharmaceuticals is displaying above average volatility of 8.63 over selected time horizon. Investors should scrutinize Easton Pharmaceuticals independently to make sure intended market timing strategies are aligned with expectations about Easton Pharmaceuticals volatility. Easton Pharmaceuticals is a penny stock. Even though Easton Pharmaceuticals may be a good instrument to invest, many penny stocks are speculative instruments that are subject to artificial stock promotions. Please make sure you fully understand upside and downside potential of investing in Easton Pharmaceuticals or similar risky assets. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings,sudden promotions and many other similar artificial hype indicators. We also encourage traders to check work history of company executives before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on this equity instrument if you perfectly time your entry and exit. However, remember that penny stocks that has been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The one and only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.
    
 Better Than Average     
    
 Worse Than Average Compare Easton Pharmaceuticals to competition

Easton Pharmaceuticals Fundamental Vs Peers

FundamentalsEaston PharmaceuticalsPeer Average
Return On Asset(27.79) (0.14) 
Current Valuation2.43 M16.62 B
Shares Owned by Institutions0.01 39.21 
Price to Earning(22.00) 28.72 
Price to Book2.60 9.51 
Price to Sales41.50 11.42 
Revenue67.43 K9.43 B
Gross Profit153 K27.38 B
Net Income(526.78 K)570.98 M
Cash and Equivalents5.81 K2.7 B
Total Debt15.4 K5.32 B
Debt to Equity1.20 48.70 
Current Ratio2.28 2.16 
Cash Flow from Operations(155.6 K)971.22 M
Earnings Per Share(0.001) 3.12 
Number of Employees818.84 K
Beta-2.53-0.15
Market Capitalization115.5 K19.03 B
Total Asset1.42 M29.47 B
Retained Earnings(37.94 M)9.33 B
Working Capital160 K1.48 B
Current Asset297 K9.34 B
Current Liabilities137 K7.9 B
Z Score-32.28.72

Easton Pharmaceuticals Market Momentum

Search macroaxis.com